This early-phase clinical trial is testing a new treatment called brenetafusp (IMC-F106C) for adults with advanced cancers that test positive for a specific protein called PRAME. Brenetafusp is a type of immunotherapy known as an ImmTAC®, which is designed to help the immune system find and destroy cancer cells.
To take part in the trial, patients must also have a particular tissue marker called HLA-A2, which is found through routine testing.
The trial will be carried out in two parts:
- Phase 1 will focus on finding the safest dose of brenetafusp, either on its own or in combination with other treatments such as chemotherapy, targeted therapy, or other immunotherapies.
- Phase 2 will explore how well brenetafusp works in shrinking or controlling selected types of advanced cancers.
This is the first time brenetafusp is being tested in humans, so the study will carefully monitor safety and side effects, as well as how the drug behaves in the body and its impact on the cancer.